Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Amin O. Elzupir. (2022) Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics 40:5, pages 2113-2120.
Read now
Read now
Tomohiro Ito, Yusuke Naito, Naoki Shimmoto, Kaori Ochiai, Naoyuki Hayashi & Tomoo Okamura. (2021) Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance. Expert Opinion on Drug Safety 20:3, pages 363-372.
Read now
Read now
Luis M. Pérez-Belmonte, Julio Osuna-Sánchez, Mercedes Millán-Gómez, María D. López-Carmona, Juan J. Gómez-Doblas, Lidia Cobos-Palacios, Jaime Sanz-Cánovas, Miguel A. Barbancho, José P. Lara, Manuel Jiménez-Navarro, M. Rosa. Bernal-López & Ricardo Gómez-Huelgas. (2019) Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. Annals of Medicine 51:3-4, pages 252-261.
Read now
Read now
Baptist Gallwitz. (2015) Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. Therapeutics and Clinical Risk Management 11, pages 799-805.
Read now
Read now
Hiroyuki Ito, Mariko Abe, Shinichi Antoku, Takashi Omoto, Masahiro Shinozaki, Shinya Nishio, Mizuo Mifune & Michiko Togane. (2015) Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment – retrospective observation study of Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 16:3, pages 289-296.
Read now
Read now
Karoline von Websky, Christoph Reichetzeder & Berthold Hocher. (2013) Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vascular Health and Risk Management 9, pages 681-694.
Read now
Read now
Baptist Gallwitz. (2013) Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 6, pages 1-9.
Read now
Read now
George Grunberger. (2013) Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin. Postgraduate Medicine 125:3, pages 79-90.
Read now
Read now
Stephanie Aleskow Stein, Elizabeth Mary Lamos & Stephen N Davis. (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opinion on Drug Safety 12:2, pages 153-175.
Read now
Read now
Lene Hoimark, Torben Laursen & Jørgen Rungby. (2012) Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 5, pages 295-302.
Read now
Read now
Sylvie Dejager & Anja Schweizer. (2012) Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment. Hospital Practice 40:2, pages 7-21.
Read now
Read now
Thomas Forst & Andreas Pfützner. (2012) Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 13:1, pages 101-110.
Read now
Read now
André J Scheen. (2011) Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opinion on Drug Metabolism & Toxicology 7:12, pages 1561-1576.
Read now
Read now
Scott E. Nelson. (2011) Management of patients with type 2 diabetes. Current Medical Research and Opinion 27:10, pages 1931-1947.
Read now
Read now
Baptist Gallwitz. (2011) Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opinion on Investigational Drugs 20:6, pages 723-732.
Read now
Read now
Isabelle Bourdel-Marchasson, Anja Schweizer & Sylvie Dejager. (2011) Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus. Hospital Practice 39:1, pages 7-21.
Read now
Read now
Nigel Irwin, Victor Gault & Peter R Flatt. (2010) Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?. Expert Opinion on Investigational Drugs 19:9, pages 1039-1048.
Read now
Read now
Articles from other publishers (90)
Israa M Nour, Ahmed R Mohamed & Mohamed Badrawy. (2023) Innovative UV Protocols Based on Straightforward Mathematical Filtration for Concurrent Estimation of Two Antidiabetic Drugs in Their Brand-New Combination: A Comparative Study. Journal of AOAC International.
Crossref
Crossref
Ahmed Abdulhafez Hamad, Bassam S. Mohammed, Yasser F. Hassan, Afnan S. Batubara & Ahmed M. Haredy. (2023) Facile decoration of one-pot fluorescence probe-patterned reaction for sensing and ultrasensitive determination of tradjenta, a new type 2 diabetes oral therapy. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 298, pages 122808.
Crossref
Crossref
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Ahmed A. Abu-hassan, Mohamed A. El Hamd, Mahmoud H. El-Maghrabey, Wael A. Mahdi, Sultan Alshehri & Bassam Shaaban Mohammed. (2023) Application of isoindole fluorophore formation for determination of linagliptin in the sole and co-formulated tablets: Application for plasma assay and content uniformity testing. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 291, pages 122390.
Crossref
Crossref
Mozhgan Karimifar, Jamileh Afsar, Massoud Amini, Firouzeh Moeinzadeh, Awat Feizi & Ashraf Aminorroaya. (2023) The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial. Scientific Reports 13:1.
Crossref
Crossref
Manal S. Elmasry, Wafaa S. Hassan, Hanan A. Merey & Israa M. Nour. (2021) Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 254, pages 119609.
Crossref
Crossref
Pranav Shah, Kejal Chavda, Bhavin Vyas & Shailaja Patel. (2020) Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Delivery and Translational Research 11:3, pages 1166-1185.
Crossref
Crossref
Ramji Rathod, Faraat Ali, Amrish Chandra, Robin Kumar, Meenakshi Dahiya & Gyanendra Nath Singh. (2021) Simultaneous Determination of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin in Bulk Drug and Formulation by UPLC Q-TOF-MS. Current Pharmaceutical Analysis 17:1, pages 95-105.
Crossref
Crossref
Zhou Guoquan, Shao Danfeng, Shen Jian & Yang Zehui. (2021) Solubility profiles of linagliptin in pure and mixed solvents: Interactions and thermodynamic parameters. The Journal of Chemical Thermodynamics 152, pages 106273.
Crossref
Crossref
Taras S. Panevin, Olga V. Zhelyabina, Maxim S. Eliseev & Marina V. Shestakova. (2020) Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes mellitus 23:4, pages 349-356.
Crossref
Crossref
Omnia S. El‐Deeb, Gehan M. Soliman & Rasha O. Elesawy. (2020) Linagliptin, the dipeptidyl peptidase‐4 enzyme inhibitor, lessens CHOP and GRP78 biomarkers levels in cisplatin‐induced neurobehavioral deficits: A possible restorative gateway. Journal of Biochemical and Molecular Toxicology 34:9.
Crossref
Crossref
Yara M. Aboulmagd, Alshaymaa A.Z. El-Bahy, Esther T. Menze, Samar S. Azab & Ebtehal El-Demerdash. (2020) Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats. European Journal of Pharmacology 881, pages 173224.
Crossref
Crossref
Sujuan Ding, Sheng Xu, Yong Ma, Gang Liu, Hongmei Jang & Jun Fang. (2019) Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes. Biomolecules 9:12, pages 850.
Crossref
Crossref
Marile Santamarina & Curt J. Carlson. (2019) Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. BMC Cardiovascular Disorders 19:1.
Crossref
Crossref
Hiroshi Takahashi, Rimei Nishimura, Daisuke Tsujino & Kazunori Utsunomiya. (2018) Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study. Journal of Diabetes Investigation 10:3, pages 714-722.
Crossref
Crossref
Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou & Tien-Hsing Chen. (2018) Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovascular Diabetology 17:1.
Crossref
Crossref
Geert Jan Biessels, Jolien Janssen, Esther van den Berg, Bernard Zinman, Mark A. Espeland, Michaela Mattheus & Odd Erik Johansen. (2018) Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. BMC Neurology 18:1.
Crossref
Crossref
Luis Pérez-Belmonte, Juan Gómez-Doblas, Mercedes Millán-Gómez, María López-Carmona, Ricardo Guijarro-Merino, Fernando Carrasco-Chinchilla, Eduardo de Teresa-Galván, Manuel Jiménez-Navarro, M. Bernal-López & Ricardo Gómez-Huelgas. (2018) Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). Journal of Clinical Medicine 7:9, pages 271.
Crossref
Crossref
Annayya R. Aroor, Javad Habibi, Hemanth Kumar Kandikattu, Mona Garro-Kacher, Brady Barron, Dongqing Chen, Melvin R. Hayden, Adam Whaley-Connell, Shawn B. Bender, Thomas Klein, Jaume Padilla, James R. Sowers, Bysani Chandrasekar & Vincent G. DeMarco. (2017) Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Sushant Jadhav, P. Reddy, Kalyanaraman Narayanan & Popatrao Bhosale. (2017) Development of RP-HPLC, Stability Indicating Method for Degradation Products of Linagliptin in Presence of Metformin HCl by Applying 2 Level Factorial Design; and Identification of Impurity-VII, VIII and IX and Synthesis of Impurity-VII. Scientia Pharmaceutica 85:3, pages 25.
Crossref
Crossref
Andrew J. Krentz & Alan J. Sinclair. 2017. Diabetes in Old Age. Diabetes in Old Age
298
322
.
Nikolaos Perakakis, Olivia M. Farr, Dario Tuccinardi, Jagriti Upadhyay & Christos S. Mantzoros. (2017) Research advances in metabolism 2016. Metabolism 67, pages 41-53.
Crossref
Crossref
Francisco J Pasquel, Roma Gianchandani, Daniel J Rubin, Kathleen M Dungan, Isabel Anzola, Patricia C Gomez, Limin Peng, Israel Hodish, Tim Bodnar, David Wesorick, Vijay Balakrishnan, Kwame Osei & Guillermo E Umpierrez. (2017) Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. The Lancet Diabetes & Endocrinology 5:2, pages 125-133.
Crossref
Crossref
Antonio Ceriello & Nobuya Inagaki. (2017) Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. Journal of Diabetes Investigation 8:1, pages 19-28.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
127
146
.
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Abeer Hanafy & Hoda Mahgoub. (2016) A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. Journal of Chromatographic Science 54:9, pages 1573-1577.
Crossref
Crossref
Shan-yao Ma, Meng-meng Ning, Qing-an Zou, Ying Feng, Yang-liang Ye, Jian-hua Shen & Ying Leng. (2016) OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition. Acta Pharmacologica Sinica 37:10, pages 1359-1369.
Crossref
Crossref
Xueying Tan & Jingbo Hu. (2016) Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Annales d'Endocrinologie 77:5, pages 557-562.
Crossref
Crossref
Akiko Sarashina, Christian Friedrich, Susanne Crowe, Sanjay Patel, Ulrike Graefe-Mody, Naoyuki Hayashi & Yoshiharu Horie. (2016) Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes. Journal of Diabetes Investigation 7:5, pages 744-750.
Crossref
Crossref
Matthias Kern, Nora Kl?ting, Michael Mark, Eric Mayoux, Thomas Klein & Matthias Bl?her. (2016) The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 65:2, pages 114-123.
Crossref
Crossref
Yuichiro Ueda, Hiroki Ishii, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, Kiyonori Ito, Keiji Hirai, Yoshio Kaku, Honami Mori, Taro Hoshino, Susumu Ookawara, Masafumi KakeiKaoru TabeiYoshiyuki Morishita. (2017) Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers. Drug Target Insights 10, pages DTI.S38339.
Crossref
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle & Odd Erik Johansen. (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Sneha R. Sagar, Jessica K. Agarwal, Dhaivat H. Pandya, Ranjeet Prasad Dash, Manish Nivsarkar & Kamala K. Vasu. (2015) Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes. Bioorganic & Medicinal Chemistry Letters 25:20, pages 4428-4433.
Crossref
Crossref
Louise S. Dalbøge, Philip J. Pedersen, Gitte Hansen, Katrine Fabricius, Henrik B. Hansen, Jacob Jelsing & Niels Vrang. (2015) A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents. PLOS ONE 10:8, pages e0135634.
Crossref
Crossref
Ruijun Han, Xinying Wang, William Bachovchin, Zofia Zukowska & John W. Osborn. (2015) Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation. Scientific Reports 5:1.
Crossref
Crossref
Silke Retlich, Vincent Duval, Ulrike Graefe-Mody, Christian Friedrich, Sanjay Patel, Ulrich Jaehde & Alexander Staab. (2015) Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 54:7, pages 737-750.
Crossref
Crossref
Nikolaus Marx, Julio Rosenstock, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Mark A Espeland, Erich Bluhmki, Michaela Mattheus, Bart Ryckaert, Sanjay Patel, Odd Erik Johansen & Hans-Juergen Woerle. (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA
®
)
. Diabetes and Vascular Disease Research 12:3, pages 164-174.
Crossref
Crossref
Di-Wei Mo, Shuai Dong, Haiyan Sun, Jia-Sheng Chen, Jian-Xin Pang, Bao-Min Xi & Wen-Hua Chen. (2015) Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorganic & Medicinal Chemistry Letters 25:9, pages 1872-1875.
Crossref
Crossref
Abdallah Al Eyadeh & Paul E Jennings. (2015) New pharmacological approaches to diabetes management. Practice Nursing 26:3, pages 140-146.
Crossref
Crossref
Junhao Xing, Qing Li, Shengping Zhang, Haomiao Liu, Leilei Zhao, Haibo Cheng, Yuan Zhang, Jinpei Zhou & Huibin Zhang. (2014)
Identification of Dipeptidyl Peptidase
IV
Inhibitors: Virtual Screening, Synthesis and Biological Evaluation
. Chemical Biology & Drug Design 84:3, pages 364-377.
Crossref
Crossref
Heike Zimdahl, Carina Ittrich, Ulrike Graefe-Mody, Bernhard O. Boehm, Michael Mark, Hans-Juergen Woerle & Klaus A. Dugi. (2014) Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 57:9, pages 1869-1875.
Crossref
Crossref
Ulrike Graefe-Mody, Christian FriedrichMaximilian von Eynatten, Sandra Thiemann, Tim Heise & Hans-Juergen Woerle. (2014)
Letter to the editor regarding: “Pharmacokinetics of teneligliptin in subjects with renal impairment.” Halabi
et al
.,
Clinical Pharmacology in Drug Development
2013;2:246-254
. Clinical Pharmacology in Drug Development 3:5, pages 417-418.
Crossref
Crossref
Michael Lehrke, Nikolaus Marx, Sanjay Patel, Thomas Seck, Susanne Crowe, Karen Cheng, Maximilian von Eynatten & Odd Erik Johansen. (2014) Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. Clinical Therapeutics 36:8, pages 1130-1146.
Crossref
Crossref
Alexandre Hohl. (2014) Linagliptin: DPP-4 Inhibition in the Treatment of Type 2 Diabetes Mellitus. Journal of Diabetes, Metabolic Disorders & Control 1:1.
Crossref
Crossref
Vladimer Darsalia, Anna Olverling, Martin Larsson, Shiva Mansouri, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm & Cesare Patrone. (2014) Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory Peptides 190-191, pages 25-31.
Crossref
Crossref
Yifei Zhang, Jie Hong, Jie Chi, Weiqiong Gu, Guang Ning & Weiqing Wang. (2014) Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes/Metabolism Research and Reviews 30:3, pages 241-256.
Crossref
Crossref
Sri Harsha Tella, Halis Kaan Akturk & Marc Rendell. (2014) Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4:1, pages 85-101.
Crossref
Crossref
Erika Paniago Guedes, Alexandre Hohl, Thais Gomes de Melo & Felipe Lauand. (2013) Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetology & Metabolic Syndrome 5:1.
Crossref
Crossref
Guillermo E. Umpierrez & Luigi Meneghini. (2013) Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. Endocrine Practice 19:4, pages 718-728.
Crossref
Crossref
Annayya R. Aroor, James R. Sowers, Shawn B. Bender, Ravi Nistala, Mona Garro, Irina Mugerfeld, Melvin R. Hayden, Megan S. Johnson, Muhammad Salam, Adam Whaley-Connell & Vincent G. DeMarco. (2013) Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats. Endocrinology 154:7, pages 2501-2513.
Crossref
Crossref
Baptist Gallwitz. (2013) Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Therapeutic Advances in Endocrinology and Metabolism 4:3, pages 95-105.
Crossref
Crossref
Janet B. McGill, Lance Sloan, Jennifer Newman, Sanjay PatelChristophe Sauce, Maximilian von Eynatten & Hans-Juergen Woerle. (2013) Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Care 36:2, pages 237-244.
Crossref
Crossref
Naoki Ishiguro, Hidetada Shimizu, Wataru Kishimoto, Thomas Ebner & Olaf Schaefer. (2013) Evaluation and Prediction of Potential Drug-Drug Interactions of Linagliptin Using In Vitro Cell Culture Methods. Drug Metabolism and Disposition 41:1, pages 149-158.
Crossref
Crossref
Aiying Wang, Charles Dorso, Lisa Kopcho, Gregory Locke, Robert Langish, Eric Harstad, Petia Shipkova, Jovita Marcinkeviciene, Lawrence Hamann & Mark S Kirby. (2012) Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacology 12:1.
Crossref
Crossref
Thomas Rauch, Ulrike Graefe-Mody, Carolyn F. Deacon, Arne Ring, Jens J. Holst, Hans-Juergen Woerle, Klaus A. Dugi & Tim Heise. (2012) Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy 3:1.
Crossref
Crossref
Chrysi Koliaki & John Doupis. (2012) Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology. Advances in Therapy 29:12, pages 993-1004.
Crossref
Crossref
J. Jelsing, N. Vrang, S. B. van Witteloostuijn, M. Mark & T. Klein. (2012) The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves ?-cell mass in non-obese diabetic mice. Journal of Endocrinology 214:3, pages 381-387.
Crossref
Crossref
Matthias Kern, Nora Kl?ting, Heiko G. Niessen, Leo Thomas, Detlef Stiller, Michael Mark, Thomas Klein & Matthias Bl?her. (2012) Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity. PLoS ONE 7:6, pages e38744.
Crossref
Crossref
T. Haak, T. Meinicke, R. Jones, S. Weber, M. von Eynatten & H.‐J. Woerle. (2012) Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes, Obesity and Metabolism 14:6, pages 565-574.
Crossref
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Crossref
Holger Fuchs, Frank Runge & Heinz-Dieter Held. (2012) Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. European Journal of Pharmaceutical Sciences 45:5, pages 533-538.
Crossref
Crossref
Sten Madsbad. (2012) Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. European Journal of Internal Medicine 23:2, pages 132-136.
Crossref
Crossref
Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo & Edoardo Mannucci. (2012) Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?. Advances in Therapy 29:3, pages 218-233.
Crossref
Crossref
Bo Ahrén. (2011) DPP‐4 inhibition and islet function. Journal of Diabetes Investigation 3:1, pages 3-10.
Crossref
Crossref
Jon M. Sutton, David E. Clark, Stephen J. Dunsdon, Garry Fenton, Amanda Fillmore, Neil V. Harris, Chris Higgs, Chris A. Hurley, Sussie L. Krintel, Robert E. MacKenzie, Alokesh Duttaroy, Eric Gangl, Wiesia Maniara, Richard Sedrani, Kenji Namoto, Nils Ostermann, Bernd Gerhartz, Finton Sirockin, J?rg Trappe, Ulrich Hassiepen & Daniel K. Baeschlin. (2012) Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters 22:3, pages 1464-1468.
Crossref
Crossref
Baptist Gallwitz. (2012) Linagliptin–-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy. Clinical Medicine Insights: Endocrinology and Diabetes 5, pages CMED.S7274.
Crossref
Crossref
Odd Johansen, Dietmar Neubacher, Maximilian von Eynatten, Sanjay Patel & Hans-Juergen Woerle. (2012) Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular Diabetology 11:1, pages 3.
Crossref
Crossref
Markus L. Alter, Ina M. Ott, Karoline von Websky, Oleg Tsuprykov, Yuliya Sharkovska, Katharina Krause-Relle, Jens Raila, Andrea Henze, Thomas Klein & Berthold Hocher. (2012) DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy. Kidney and Blood Pressure Research 36:1, pages 119-130.
Crossref
Crossref
D. R. Owens, R. Swallow, K. A. Dugi & H. J. Woerle. (2011) Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabetic Medicine 28:11, pages 1352-1361.
Crossref
Crossref
Juergen Sandow. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Rohit Kohli, Margaret A. Stefater & Thomas H. Inge. (2011) Molecular insights from bariatric surgery. Reviews in Endocrine and Metabolic Disorders 12:3, pages 211-217.
Crossref
Crossref
Ulrike Graefe-Mody, Thomas Giessmann, Arne Ring, Mario Iovino & Hans-Juergen Woerle. (2011) A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects. Clinical Therapeutics 33:8, pages 1096-1103.
Crossref
Crossref
Arne Ring, Andreas Port, E. Ulrike Graefe-Mody, Ivette Revollo, Mario Iovino & Klaus A. Dugi. (2011) The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. British Journal of Clinical Pharmacology 72:1, pages 39-50.
Crossref
Crossref
Yoshiharu Horie, Shigeto Kanada, Hirotaka Watada, Akiko Sarashina, Atsushi Taniguchi, Naoyuki Hayashi, Eva U. Graefe-Mody, Hans-Juergen Woerle & Klaus A. Dugi. (2011) Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients. Clinical Therapeutics 33:7, pages 973-989.
Crossref
Crossref
T. Forst, B. Uhlig-Laske, A. Ring, A. Ritzhaupt, U. Graefe-Mody & K. A. Dugi. (2011) The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 13:6, pages 542-550.
Crossref
Crossref
Bo Ahrén. (2011) GLP-1 for type 2 diabetes. Experimental Cell Research 317:9, pages 1239-1245.
Crossref
Crossref
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, pages 83-90.
Crossref
Crossref
C. Friedrich, A. Ring, T. Brand, R. Sennewald, E. U. Graefe-Mody & H.-J. Woerle. (2011) Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 36:1, pages 17-24.
Crossref
Crossref
Ulrike Graefe-Mody, Peter Rose, Arne Ring, Kerstin Zander, Mario Iovino & Hans-Juergen Woerle. (2011) Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects. Drug Metabolism and Pharmacokinetics 26:2, pages 123-129.
Crossref
Crossref
M.-R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K. A. Dugi & H.-J. Woerle. (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism 13:1, pages 65-74.
Crossref
Crossref
Michael A. Nauck. (2011) Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. The American Journal of Medicine 124:1, pages S3-S18.
Crossref
Crossref
T. Forst, B. Uhlig-Laske, A. Ring, U. Graefe-Mody, C. Friedrich, K. Herbach, H.-J. Woerle & K. A. Dugi. (2010) Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine 27:12, pages 1409-1419.
Crossref
Crossref
John Gerich. (2010) DPP-4 inhibitors: What may be the clinical differentiators?. Diabetes Research and Clinical Practice 90:2, pages 131-140.
Crossref
Crossref
André J. Scheen. (2010) Dipeptidylpeptitase-4 Inhibitors (Gliptins). Clinical Pharmacokinetics 49:9, pages 573-588.
Crossref
Crossref
Andreas Greischel, Rudolf Binder & Juergen Baierl. (2010) The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Exhibits Time- and Dose-Dependent Localization in Kidney, Liver, and Intestine after Intravenous Dosing: Results from High Resolution Autoradiography in Rats. Drug Metabolism and Disposition 38:9, pages 1443-1448.
Crossref
Crossref
A. J. Scheen. (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, Obesity and Metabolism 12:8, pages 648-658.
Crossref
Crossref
Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima, Naoyuki Hayashi, Atsushi Taniguchi, Yoshiharu Horie, Eva U. Graefe-Mody, Hans-Juergen Woerle & Klaus A. Dugi. (2010) Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects. Clinical Therapeutics 32:6, pages 1188-1204.
Crossref
Crossref